RT Journal Article
T1 Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study
A1 Cavagna, Lorenzo
A1 Nuño, Laura
A1 Scirè, Carlo Alberto
A1 Govoni, Marcello
A1 Lopez Longo, Francisco Javier
A1 Franceschini, Franco
A1 Neri, Rossella
A1 Castañeda, Santos
A1 Sifuentes Giraldo, Walter Alberto
A1 Caporali, Roberto
A1 Iannone, Florenzo
A1 Fusaro, Enrico
A1 Paolazzi, Giuseppe
A1 Pellerito, Raffaele
A1 Schwarting, Andreas
A1 Saketkoo, Lesley Ann
A1 Ortego-Centeno, Norberto
A1 Quartuccio, Luca
A1 Bartoloni, Elena
A1 Specker, Christof
A1 Pina Murcia, Trinitario
A1 La Corte, Renato
A1 Furini, Federica
A1 Foschi, Valentina
A1 Bachiller Corral, Javier
A1 Airò, Paolo
A1 Cavazzana, Ilaria
A1 Martínez-Barrio, Julia
A1 Hinojosa, Michelle
A1 Giannini, Margherita
A1 Barsotti, Simone
A1 Menke, Julia
A1 Triantafyllias, Kostantinos
A1 Vitetta, Rosetta
A1 Russo, Alessandra
A1 Bajocchi, Gianluigi
A1 Bravi, Elena
A1 Barausse, Giovanni
A1 Bortolotti, Roberto
A1 Selmi, Carlo
A1 Parisi, Simone
A1 Montecucco, Carlomaurizio
A1 González-Gay, Miguel Angel
K1 Anticuerpos antinucleares
K1 Artritis
K1 Humanos
K1 Miositis
K1 Estudios retrospectivos
K1 Femenino
K1 Masculino
AB Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). These manifestations usually co-occur (for practical purpose complete forms) in the same patient, but cases with only 1 or 2 of these findings (for practical purpose incomplete forms) have been described. In incomplete forms, the ex novo occurrence of further manifestations is possible, although with frequencies and timing not still defined. The aim of this international, multicenter, retrospective study was to characterize the clinical time course of anti Jo-1 positive ASSD in a large cohort of patients. Included patients should be anti Jo-1 positive and with at least 1 feature between arthritis, myositis, and ILD. We evaluated the differences between complete and incomplete forms, timing of clinical picture appearance and analyzed factors predicting the appearance of further manifestations in incomplete ASSD. Finally, we collected 225 patients (58 males and 167 females) with a median follow-up of 80 months. At the onset, complete ASSD were 44 and incomplete 181. Patients with incomplete ASSD had frequently only 1 of the classic triad findings (110 cases), in particular, isolated arthritis in 54 cases, isolated myositis in 28 cases, and isolated ILD in 28 cases. At the end of follow-up, complete ASSD were 113, incomplete 112. Only 5 patients had an isolated arthritis, only 5 an isolated myositis, and 15 an isolated ILD. During the follow-up, 108 patients with incomplete forms developed further manifestations. Single main feature onset was the main risk factor for the ex novo appearance of further manifestation. ILD was the prevalent ex novo manifestation (74 cases). In conclusion, ASSD is a condition that should be carefully considered in all patients presenting with arthritis, myositis, and ILD, even when isolated. The ex novo appearance of further manifestations in patients with incomplete forms is common, thus indicating the need for an adequate clinical and instrumental follow-up. Furthermore, the study clearly suggested that in ASSD multidisciplinary approach involving Rheumatology, Neurology, Pneumology, and Internal Medicine specialists is mandatory.
PB Lippincott, Williams & Wilkins
SN 0025-7974
YR 2015
FD 2015-08
LK http://hdl.handle.net/10668/2634
UL http://hdl.handle.net/10668/2634
LA en
NO Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJ, Franceschini L, et al. Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. 2015 Medicine (Baltimore).  Aug;94(32):e1144.
DS RISalud
RD Apr 6, 2025